Net costs of dementia in Sweden - An Incidence Based 10 Year Simulation Study

International Journal of Geriatric Psychiatry

Volumn 27, Issue 11, 2012, Pages 1112-1117

  Sköldunger, Anders ^a   Wimo, Anders ^b   Johnell, Kristina ^a  

^a AGING RESEARCH CENTER   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

costs; dementia; drugs; health economy; incidence based; informal care; modeling; simulation

Indexed keywords

ADULT; AGED; AGING; ARTICLE; COHORT ANALYSIS; DEMENTIA; DISEASE SEVERITY; FEMALE; HEALTH CARE COST; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; SIMULATION; SWEDEN;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COSTS AND COST ANALYSIS; DEMENTIA; FEMALE; HEALTH CARE COSTS; HUMANS; INCIDENCE; INSTITUTIONALIZATION; MALE; MARKOV CHAINS; MIDDLE AGED; SWEDEN;

EID: 84867335997     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2828     Document Type: Article

References (38)

1. Aguero-Torres H, Qiu C, Winblad B, Fratiglioni L,. 2002. Dementing disorders in the elderly: evolution of disease severity over 7 years. Alzheimer Dis Assoc Disord 16: 221-227.
2. Berg L,. 1988. Clinical dementia rating (CDR). Psychopharmacol Bull 24: 637-639.
3. Buxton MJ, Drummond MF, Van Hout BA, et al., 1997. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 6: 217-227.
4. Caro JJ., 2005. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23: 323-332.
5. Ernst RL, Hay JW,. 1994. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 84: 1261-1264.
6. Faissol DM, Griffin PM, Swann JL,. 2009. Bias in Markov models of disease. Math Biosci 220: 143-156.
7. Fenn P, Gray A,. 1999. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach. Pharmacoeconomics 16: 165-174.
8. Fratiglioni L, De Ronchi D, Aguero-Torres H,. 1999. Worldwide prevalence and incidence of dementia. Drugs Aging 15: 365-375.
9. Fratiglioni L, Launer LJ, Andersen K, et al., 2000 Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54: S10-5.
10. Fratiglioni L, Viitanen M, Backman L, Sandman PO, Winblad B,. 1992. Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology 11 (Suppl 1): 29-36.
11. Genvigir FD, Rodrigues AC, Cerda A, et al., 2010. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics 11: 1235-1246.
12. Haasum Y, Fastbom J, Fratiglioni L, Johnell K,. 2011. Undertreatment of osteoporosis in persons with dementia? A population-based study. Osteoporos Int. [Epub ahead of print] Epubdate 2011/04/19.
13. Johnell K, Weitoft GR, Fastbom J,. 2008. Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disord 25: 54-59.
14. Jonsson L, Lindgren P, Wimo, A, Jonsson B, Winblad B,. 1999. Costs of Mini mental state examination-related cognitive impairment. Pharmacoeconomics 16: 409-416.
15. Klarin I, Fastbom J, Wimo A,. 2003 A population-based study of drug use in the very old living in a rural district of Sweden, with focus on cardiovascular drug consumption: comparison with an urban cohort. Pharmacoepidemiol Drug Saf 12: 669-678.
16. Lagergren M, Holst G, Rahm-Hallberg I, Wimo A,. 2002. Behov och insatser för de äldrei i SNAC-kommunerna. Jämförelser från SNAC baslinjeundersökningar 2001 i Karlskrona, på Kungsholmen, i Nordanstig och i Skåne. Stockholm, Gerontology Research Center (Stiftelsen Îldrecentrum).
17. Lovestone S., 2002. Can we afford to develop treatments for dementia? J Neurol Neurosurg Psychiatry 72: 685.
18. Marengoni A, Rizzuto D, Wang HX, Winblad B, Fratiglioni L,. 2009. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc 57: 225-230.
19. MICROSOFT. 2010. C. Microsoft Excel 2010.
20. Nordberg G, Wimo A, Jönsson L, et al., 2007. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project-a population based study in Sweden. Int J Geriatric Psychiatry 20: 862-871.
21. Nordberg G, Von Strauss E, Kareholt I, Johansson L, Wimo A,. 2005. The amount of informal and formal care among non-demented and demented elderly persons-results from a Swedish population-based study. Int J Geriatr Psychiatry 20: 862-871.
22. Palmer K, Wang HX, Backman L, Winblad B, Fratiglioni L,. 2002. Differential evolution of cognitive impairment in nondemented older persons: results from the Kungsholmen Project. Am J Psychiatry 159: 436-442.
23. Reisberg B, Franssen E, Souren LE, Kenowsky S, Auer S,. 1998. Severity scales. In, Wimo A, Jönsson B, Karlsson G, Winblad B, (Eds.) The Health Economics of Dementia. London, John Wiley and Sons.
24. RIKSBANK.SE. 2010. http://www.riksbank.se/templates/stat.aspx?id=16749. Sveriges Riksbank.
25. SBU. 2008. Dementia. A Systematic Review. Stockholm, Staten beredning för medicinsk utvärdering (SBU) (The Swedish Council on Technology Assessment in Health Care).
26. SKL. 2005. Kostnadsuppgifter mm per DRG totalt för databasen 2005.
27. SKL. 2007. Hemtjänsttimmen-vad kostar en timme direkt brukartid? Stockholm, Sveriges Kommuner och Landsting (SKL).
28. SOCIALSTYRELSEN. 2006. Jämförelsetal för socialtjänsten 2005. Stockholm, Socialstyrelsen.
29. Sonnenberg FA, Leventhal EA,. 1998. Modeling disease progression with Markov models. In, Wimo A, Jonsson B, Karlsson G, Winblad B, (Eds.) Health Economics of Dementia. London, John Wiley and Sons.
30. TREEAGE SOFTWARE. 2009. I. Tree Age Pro Suite 2009. Release 1.0.2 ed. Williamstown, MA.
31. Wimo A, Johansson L, Jönsson L,. 2007a. Demenssjukdomarnas samhällskostnader och antalet dementa i Sverige 2005 (The societal costs of dementia and the number of demented in Sweden 2005) (in Swedish). In Socialstyrelsen (Ed.) Underlag Från Experter. Stockholm, Socialstyrelsen.
32. Wimo A, Johansson I, Jönsson L,. 2009. Har demenssjukdomarnas samhällskostnader förändrats mellan 2000 och 2005? Lakartidningen; 1277-1282.
33. Wimo A, Jönsson L, Winblad B,. 2007b. An estimate of the total worldwide societal costs of dementia in 2005. Alzheimers Dement 3: 81-91.
34. Wimo A, Karlsson G, Winblad B,. 2005. Health economic aspects of dementia. In, Burns A, O'Brien J, Ames D, (Eds.) Dementia. 3rd ed. London, Hodder & Stoughton Educationa l.
35. Wimo A, Sjolund B, Skoldunger A, et al., 2011. Incremental patterns in the amount of informal and formal care among non-demented and demented elderly persons: results from a 3-year follow-up population-based study. Int J Geriatr Psychiatry 1: 56-64.
36. Wimo A, Wetterholm AL, Mastey V, Winblad B,. 1998. Evaluation of the resource utilization and caregiver time in anti-dementia drug trials - a quantitative battery. In, Wimo A, Jonsson B, Karlsson G, Winblad B, (Eds.) The Health Economics of Dementia. London, John Wiley & Sons.
37. Wimo A, Winblad B, Aguero TH, Von Strauss E,. 2003. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord, 17, 63-67.
38. VÎGVERKET. 1997. Vägverkets samhällsekonomiska kalkylmodell. Ekonomisk teori och värderingar. Stockholm, Vägverket (Swedish Road Authority).